Fig. 1

Audit design: Chronic migraine patients who failed at least 3 preventive treatments, with or without medication overused, were offered monthly subcutaneous injections of erenumab at 70 mg for 3 months. At the three-month time point, patients who achieved at least a 50% reduction in migraine days, were offered the option to continue their treatment with monthly injections of erenumab at 70 mg. Patients who achieved less than 50% reduction in their migraine days, were offered the option to receive monthly injections of erenumab at 140 mg for the next three consecutive months. Any patient who achieved less than 30% reduction in their migraine days at the six-month time point discontinued the erenumab treatment, while patients who achieved at least 30% reduction in their migraine days continue the erenumab treatment at 140 mg